95 related articles for article (PubMed ID: 15068500)
21. Diagnosis and management of bone fragility in diabetes: an emerging challenge.
Ferrari SL; Abrahamsen B; Napoli N; Akesson K; Chandran M; Eastell R; El-Hajj Fuleihan G; Josse R; Kendler DL; Kraenzlin M; Suzuki A; Pierroz DD; Schwartz AV; Leslie WD;
Osteoporos Int; 2018 Dec; 29(12):2585-2596. PubMed ID: 30066131
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.
Anagnostis P; Paschou SA; Gkekas NN; Artzouchaltzi AM; Christou K; Stogiannou D; Vryonidou A; Potoupnis M; Goulis DG
Endocrine; 2018 Jun; 60(3):373-383. PubMed ID: 29411304
[TBL] [Abstract][Full Text] [Related]
23. Diabetes, bone and glucose-lowering agents: clinical outcomes.
Schwartz AV
Diabetologia; 2017 Jul; 60(7):1170-1179. PubMed ID: 28451714
[TBL] [Abstract][Full Text] [Related]
24. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
25. Advanced Glycation End Products, Diabetes, and Bone Strength.
Yamamoto M; Sugimoto T
Curr Osteoporos Rep; 2016 Dec; 14(6):320-326. PubMed ID: 27704396
[TBL] [Abstract][Full Text] [Related]
26. Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN).
Chang PY; Gold EB; Cauley JA; Johnson WO; Karvonen-Gutierrez C; Jackson EA; Ruppert KM; Lee JS
J Clin Endocrinol Metab; 2016 Sep; 101(9):3297-305. PubMed ID: 27294327
[TBL] [Abstract][Full Text] [Related]
27. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.
Epstein S; Defeudis G; Manfrini S; Napoli N; Pozzilli P;
Osteoporos Int; 2016 Jun; 27(6):1931-51. PubMed ID: 26980458
[TBL] [Abstract][Full Text] [Related]
28. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women.
Costa AG; Walker MD; Zhang CA; Cremers S; Dworakowski E; McMahon DJ; Liu G; Bilezikian JP
J Clin Endocrinol Metab; 2013 Dec; 98(12):4736-43. PubMed ID: 24037879
[TBL] [Abstract][Full Text] [Related]
29. Effects of raloxifene on bone metabolism in hemodialysis patients.
Iwamoto J
Int J Endocrinol Metab; 2012; 10(3):573-5. PubMed ID: 23843823
[No Abstract] [Full Text] [Related]
30. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
31. Domino Effect: mechanic factors role.
Nardi A; Tarantino U; Ventura L; Armotti P; Resmini G; Cozzi L; Tonini G; Ramazzina E; Rossini M
Clin Cases Miner Bone Metab; 2011 May; 8(2):38-42. PubMed ID: 22461815
[TBL] [Abstract][Full Text] [Related]
32. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Dennison EM; Compston JE; Flahive J; Siris ES; Gehlbach SH; Adachi JD; Boonen S; Chapurlat R; Díez-Pérez A; Anderson FA; Hooven FH; LaCroix AZ; Lindsay R; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Sambrook P; Silverman S; Watts NB; Greenspan SL; Premaor M; Cooper C;
Bone; 2012 Jun; 50(6):1288-93. PubMed ID: 22426498
[TBL] [Abstract][Full Text] [Related]
33. Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures.
Boonen S; Wahl DA; Nauroy L; Brandi ML; Bouxsein ML; Goldhahn J; Lewiecki EM; Lyritis GP; Marsh D; Obrant K; Silverman S; Siris E; Akesson K;
Osteoporos Int; 2011 Dec; 22(12):2915-34. PubMed ID: 21789685
[TBL] [Abstract][Full Text] [Related]
34. Bone disease in HIV infection: a practical review and recommendations for HIV care providers.
McComsey GA; Tebas P; Shane E; Yin MT; Overton ET; Huang JS; Aldrovandi GM; Cardoso SW; Santana JL; Brown TT
Clin Infect Dis; 2010 Oct; 51(8):937-46. PubMed ID: 20839968
[TBL] [Abstract][Full Text] [Related]
35. A FRAX® model for the assessment of fracture probability in Belgium.
Johansson H; Kanis JA; McCloskey EV; Odén A; Devogelaer JP; Kaufman JM; Neuprez A; Hiligsmann M; Bruyere O; Reginster JY
Osteoporos Int; 2011 Feb; 22(2):453-61. PubMed ID: 20352409
[TBL] [Abstract][Full Text] [Related]
36. Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.
Post TM; Cremers SC; Kerbusch T; Danhof M
Clin Pharmacokinet; 2010; 49(2):89-118. PubMed ID: 20067335
[TBL] [Abstract][Full Text] [Related]
37. Is bone quality associated with collagen age?
Leeming DJ; Henriksen K; Byrjalsen I; Qvist P; Madsen SH; Garnero P; Karsdal MA
Osteoporos Int; 2009 Sep; 20(9):1461-70. PubMed ID: 19330423
[TBL] [Abstract][Full Text] [Related]
38. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
[TBL] [Abstract][Full Text] [Related]
39. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.
Roux C; Fechtenbaum J; Kolta S; Isaia G; Andia JB; Devogelaer JP
Ann Rheum Dis; 2008 Dec; 67(12):1736-8. PubMed ID: 18713788
[TBL] [Abstract][Full Text] [Related]
40. Sex hormones, their receptors and bone health.
Venken K; Callewaert F; Boonen S; Vanderschueren D
Osteoporos Int; 2008 Nov; 19(11):1517-25. PubMed ID: 18392663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
